"Companies like Tempus, Flatiron Health, and Color Genomics have built billion-dollar businesses by aggregating and analyzing cancer patient data."

"Sijbrandij's personal case will not directly affect pharmaceutical markets or oncology revenue streams, but if it catalyzes faster FDA approval pathways for rare-disease treatments, it could alter the economics of small-molecule and biologics development."

"I've taken agency in the treatment of my bone cancer (osteosarcoma in the T5 vertebrae of the upper spine). After I've ran out of standard of care treatment options and there were no trials available for me I've started doing: maximum diagnostics, created new treatments, started doing treatments in parallel, and scaling this for others."

"Osteosarcoma is rare (approximately 400 new cases per year in the US). Clinical trial enrollment is therefore tight, and most patients with advanced disease face a narrow menu of options—chemotherapy, radiation, surgery—before running out of approved paths."

"By publishing his data and inviting others to join, Sijbrandij is attempting to create a patient-led research collective that operates outside institutional review boards (IRBs) and FDA approval timelines. This is not illegal—patients have the right to discuss their treatment decisions—but it exists in a regulatory gray zone."

"Sijbrandij is not a typical cancer patient. As the founder of a $6.2 billion private company (GitLab's last reported valuation), he has capital, technical infrastructure, and a platform."

"Osteosarcoma in the spine is particularly aggressive; five-year survival rates hover around 70 percent for localized disease but drop sharply once metastasis occurs."

"Organizations like the FDA have signaled openness to 「real-world evidence」 and patient registries, but they have not endorsed patients running their own treatment protocols without institutional oversight."

"If his data becomes valuable to other researchers or if his treatment decisions produce publishable outcomes, pressure will mount on regulators to formalize pathways for patient-led data collection and parallel treatment protocols."

"Osteosarcoma treatment has remained largely unchanged for 40 years. The standard protocol—neoadjuvant chemotherapy, surgery, adjuvant chemotherapy—produces five-year survival rates of approximately 70 percent in developed countries but shows minimal improvement over recent decades."

"The FDA's 21st Century Cures Act and subsequent guidance documents have explicitly encouraged the use of real-world evidence in regulatory decision-making."